Back to search results

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Breast Cancer · Breast Neoplasm · Breast Cancer Stage IV

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Precision Next Gen Oncology & Research Center, Beverly Hills, California, United States

    Contact: Study coordinator (Rebecca Godin) · RebeccaG@NextGenOnc.com · 424-777-0708
    Contact: Study coordinator (Francisco Capilla) · FranciscoC@NextGenOnc.com · 424-777-0708
    Contact: Principal Investigator (Kumar Sankhala, MD)

  • Florida Cancer Specialists / Sarah Cannon Research Institute / SCRI, Sarasota, Florida, United States

    Contact: Study coordinator (Judy S Wang, MD) · jswang@flcancer.com · 941-377-9993
    Contact: Principal Investigator (Judy S Wang, MD)

  • Sarah Cannon Research Institute/SCRI, Nashville, Tennessee, United States

    Contact: Study coordinator (Melissa Sindler) · scri.ddureferrals@scri.com · 844-482-4812
    Contact: Principal Investigator (Denise Yardley, MD)

  • FDI Clinical Research, San Juan, Puerto Rico

    Contact: Study coordinator (Mirelis Acosta-Rivera, MD) · info@fdipr.com · (787) 722-1248
    Contact: Study coordinator (Michelle Echeandia, MT, MSMT) · mecheandia@fdipr.com · (787) 722-1248
    Contact: Principal Investigator (Mirelis Acosta-Rivera, MD)
Study leads

  • Neil Sankar, MD

    Study Director

    CMO, MBQ Pharma

View source on ClinicalTrials.gov(opens in a new tab)